Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Amortization of Deferred Charges: 2019-2024

Historic Amortization of Deferred Charges for Seres Therapeutics (MCRB) over the last 6 years, with Dec 2024 value amounting to $1.4 million.

  • Seres Therapeutics' Amortization of Deferred Charges rose 17.81% to $463,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $1.8 million, marking a year-over-year increase of 106.58%. This contributed to the annual value of $1.4 million for FY2024, which is 24.06% up from last year.
  • Latest data reveals that Seres Therapeutics reported Amortization of Deferred Charges of $1.4 million as of FY2024, which was up 24.06% from $1.1 million recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' Amortization of Deferred Charges ranged from a high of $2.5 million in FY2021 and a low of $551,000 during FY2020.
  • Its 3-year average for Amortization of Deferred Charges is $1.1 million, with a median of $1.1 million in 2023.
  • Per our database at Business Quant, Seres Therapeutics' Amortization of Deferred Charges spiked by 358.44% in 2021 and then slumped by 72.09% in 2022.
  • Seres Therapeutics' Amortization of Deferred Charges (Yearly) stood at $551,000 in 2020, then skyrocketed by 358.44% to $2.5 million in 2021, then slumped by 72.09% to $705,000 in 2022, then skyrocketed by 61.56% to $1.1 million in 2023, then increased by 24.06% to $1.4 million in 2024.